Millennium Management
TVTX icon

Millennium Management’s Travere Therapeutics TVTX Stock Holding History

Millennium Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$594K Sell
20,000
-90,000
-82% -$2.69M ﹤0.01% 4675
2025
Q4 		$4.2M Buy
110,000
+9,500
+9% +$309K ﹤0.01% 3200
2025
Q3 		$2.4M Buy
+100,500
New +$1.89M ﹤0.01% 3867
2023
Q4 		– Sell
-266,100
Closed -$2.38M – 6554
2023
Q3 		$2.38M Buy
+266,100
New +$3.75M ﹤0.01% 3392

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management's TVTX Position: Q1 2026 in Review

Millennium Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 136,065 shares — an estimated $4.07M sold.

Millennium Management first reported a position in TVTX in Q1 2014 and held it in 45 quarters. The position peaked at $30M in Q3 2023. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Millennium Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 136,065 Travere Therapeutics shares in Q1 2026, an estimated $4.07M.
  • Millennium Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 45 quarters.
  • Millennium Management's Travere Therapeutics position peaked at $30M in Q3 2023.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.